Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Elucid
ElucidElucid Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
What is becoming different about Elucid over time?
Public evidence
Elucid raises $55M to commercialize cardiovascular imaging platform
MedTech Dive
Public evidence
Imaging artificial intelligence vendor Elucid raises $55M - Radiology Business
Radiology Business
Public evidence
Elucid Raises $55M to Expand Non-Invasive Cardiovascular Diagnostic Platform
HIT Consultant
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 10 public external signal(s) across 6 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Elucid through company records and external market activity.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand Elucid. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
PlaqueIQ is an AI-powered software that analyzes coronary CTA images. It identifies and quantifies different plaque components such as lipid-rich necrotic cores.According to Elucid
What Elucid states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
I have used PlaqueIQ to non-invasively quantify coronary plaque composition and distribution.
According to Elucid
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported outcome
A Web-Based Virtual Environment Behavioral Intervention as Cardiovascular Disease and Metabolic Disease Prevention Education in Persons With HIV: Evaluation of the LEARN Randomized Controlled Trial
According to JMIR Medical Informatics
Are you seeing this result?
Recent change
Elucid raises $55M to commercialize cardiovascular imaging platform
According to MedTech Dive
Have you noticed this shift?
Recent change
Imaging artificial intelligence vendor Elucid raises $55M - Radiology Business
According to Radiology Business
Have you noticed this shift?
Recent change
Elucid Raises $55M to Expand Non-Invasive Cardiovascular Diagnostic Platform
According to HIT Consultant
Have you noticed this shift?
Recent change
Sentante lands Europe’s CE mark for endovascular robot
According to MedTech Dive
A matter of record — context, not something practice can confirm.
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
- Product Overview: Elucid's PlaqueIQ™ is an advanced imaging analysis software designed to assist healthcare professionals in diagnosing and managing cardiovascular disease (CVD). It leverages artificial intelligence to non-invasively quantify and classify coronary plaque morphology, providing detailed insights…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in mixed settings
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Elucid accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Across the category
Elucid against the rest of Imaging & Diagnostics
Category intelligence reads this as Established. A sample of peers, not a census of the category.
Where Elucid may differ
Differences in what we have recorded. Never a ranking, never a quality judgement.
No first-hand account has been recorded for Elucid or for any peer we sampled in this category.
A gap across the whole category, not a fact about this technology.
Two readings that disagree
- Category intelligence reads clinical reality here as "Expanding", yet no first-hand account appears in the systems we sampled. Both readings are shown rather than reconciled.
Used another system in Imaging & Diagnostics? How does your experience compare?
A comparison across two systems tests the category, not just one product.
Connected intelligence
Category intelligence